Barclays Downgrades Esperion Therapeutics (ESPR) to Equalweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
JPMorgan Downgrades Esperion Therapeutics (ESPR) to Neutral
June 29, 2016 11:00 AM EDTJPMorgan downgraded Esperion Therapeutics (NASDAQ: ESPR) from Overweight to Neutral with a price target of $15.00.
For an analyst ratings summary and ratings history on Esperion Therapeutics click here. For more ratings news on Esperion Therapeutics click here.
Shares of Esperion Therapeutics closed at $16.18 yesterday.
... MoreRBC Capital Downgrades Esperion Therapeutics (ESPR) to Sector Perform
June 29, 2016 7:46 AM EDTRBC Capital downgraded Esperion Therapeutics (NASDAQ: ESPR) from Outperform to Sector Perform.
For an analyst ratings summary and ratings history on Esperion Therapeutics click here. For more ratings news on Esperion Therapeutics click here.
Shares of Esperion Therapeutics closed at $16.18 yesterday.
... MoreCredit Suisse Downgrades Esperion Therapeutics (ESPR) to Underperform
June 29, 2016 6:51 AM EDTCredit Suisse downgraded Esperion Therapeutics (NASDAQ: ESPR) from Neutral to Underperform with a price target of $10.00 (from $23.00) after the company's update on the development plans for bempedoic acid leave them increasingly concerned about the product's outlook in the US market.
Analyst Vamil... More
Esperion Therapeutics (ESPR) Provides Update on Bempedoic Acid; FDA Says Regulatory Pathway for LDL-C Lowering Indication Not Well Defined
June 28, 2016 4:06 PM EDT(Updated - June 28, 2016 4:10 PM EDT)
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a late-stage pharmaceutical company focused on developing and commercializing first-in-class oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today provided updates on the bempedoic acid (ETC-1002) clinical development program and regulatory plans. The clinical program has two major components: the global pivotal Phase 3 efficacy and safety studies, and the planned global cardiovascular outcomes trial (CVOT) in patients with elevated LDL-C levels who are unable to tolerate statins (statin intolerance). The Company intends to initiate global pivotal Phase 3... More
